Pearce IP BioBlast® for w/e 26 July 2024
26 July 2024 | EU | New Indication Alert: EU Approves AbbVie’s Skyrizi® (Risankizumab) for UC On 26 July 2025, AbbVie announced European Commission approval of Skyrizi® (risankizumab) for moderate to severe ulcerative colitis (UC). Skyrizi® was already …